NCT01612039View on ClinicalTrials.gov

Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Ulcerative Colitis
Interventions
DRUG

ASP3291

Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks

DRUG

Placebo

Matching placebo tablets

All Listed Sponsors
lead

Telsar Pharma Inc.

INDUSTRY

NCT01612039 - Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter